1
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9925 |
Ofatumumab
|
Others | Others |
Ofatumumab 是一种人源化靶向抗 CD20单克隆抗体。它作用于表达 CD20 的 B 淋巴细胞,能够诱导产生抗体依赖性细胞介导的细胞毒性和补体依赖性细胞毒性的作用。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00183 |
CD20 Protein, Human, Recombinant (His & Avi)
MS4A2,Ly-44,LEU-16,MS4A1,Bp35,CD20 receptor,CVID5,MS4A-1,B1,... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... | |||
TMPK-00184 |
CD20 Protein, Human, Recombinant (His & Avi), Biotinylated
MS4A-1,CD20,B-lymphocyte surface antigen B1,Membrane-spannin... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... |